Abstract 14309: Clinical Outcomes of Acute Myocardial Infarction in Hematological Cancers

Abstract

The purpose of our study is to determine hospital outcomes of acute myocardial infarction (MI) with hematological cancers and their subtypes. Method: Patient data was obtained from the Nationwide Inpatient Sample (NIS) database between years 2009-2015. Patients with a diagnosis of acute MI [non-ST segment elevation myocardial infarction and ST segment elevation myocardial infarction (NSTEMI/STEMI)] and hematological cancer subtypes were identified using validated International Classification of Diseases, 9th revision, and Clinical Modification (ICD-9-CM) codes. Statistical analysis using Pearson chi-squared test was performed to determine hospital outcomes between acute MI and hematological cancer subtypes. Results: The prevalence of NSTEMI was 1.2%, and STEMI was 0.2% in hematological cancers, n=3,027,800. Among hematological cancer subtypes, the highest prevalence of NSTEMI and STEMI was seen in lymphocytic leukemia (2.4% and 0.25%, respectively). Mortality (16.8% vs. 8.8%), hospitalization cost (25469$ ± 36763$ vs. 20534$ ± 24767$) and length of stay (8.3 days ± 10 days vs. 6.3 ± 7.8 days) were higher in the acute MI patients with hematological cancers compared to acute MI patients without cancer. Among hematological cancer patients with acute MI, the highest mortality was found in patients with myeloid leukemia (23%) followed by multiple myeloma (MM) (17.9%), lymphocytic leukemia (15.9%) and lymphoma (14.4%). The length of stay and hospitalization cost was highest in those with myeloid leukemia followed by MM, lymphocytic leukemia and lymphoma. Conclusion: This study showed that hematological cancer patients with acute MI had a higher mortality, hospitalization cost and length of stay. Among the hematological cancer subtypes, the highest mortality, length of stay and hospitalization cost was found in myeloid leukemia.